An evolved AAV variant enables efficient genetic engineering of murine T cells

William A Nyberg,Jonathan Ark,Angela To,Sylvanie Clouden,Gabriella Reeder,Joseph J Muldoon,Jing-Yi Chung,William H Xie,Vincent Allain,Zachary Steinhart,Christopher Chang,Alexis Talbot,Sandy Kim,Alan Rosales,L Patrick Havlik,Harold Pimentel,Aravind Asokan,Justin Eyquem
DOI: https://doi.org/10.1016/j.cell.2022.12.022
IF: 64.5
2023-01-19
Cell
Abstract:Precise targeting of large transgenes to T cells using homology-directed repair has been transformative for adoptive cell therapies and T cell biology. Delivery of DNA templates via adeno-associated virus (AAV) has greatly improved knockin efficiencies, but the tropism of current AAV serotypes restricts their use to human T cells employed in immunodeficient mouse models. To enable targeted knockins in murine T cells, we evolved Ark313, a synthetic AAV that exhibits high transduction efficiency in murine T cells. We performed a genome-wide knockout screen and identified QA2 as an essential factor for Ark313 infection. We demonstrate that Ark313 can be used for nucleofection-free DNA delivery, CRISPR-Cas9-mediated knockouts, and targeted integration of large transgenes. Ark313 enables preclinical modeling of Trac-targeted CAR-T and transgenic TCR-T cells in immunocompetent models. Efficient gene targeting in murine T cells holds great potential for improved cell therapies and opens avenues in experimental T cell immunology.
What problem does this paper attempt to address?